Traws Pharma, Inc.(US:TRAW)2025-08-14 13:30Financial Data and Key Metrics Changes - As of June 30, 2025, the company had cash, cash equivalents, and short-term investments of approximately $13.1 million, down from $21.3 million as of December 31, 2024 [26] - Revenue for the quarter ended June 30, 2025, was $2.7 million, a significant increase from $57,000 for the same period in 2024, primarily due to $2.7 million in deferred revenue recognized from a licensing agreement termination [26] - Research and development expenses for the second quarter of 2025 totaled $2.3 million, down from $4 million in the comparable period in 2024, reflecting decreased oncology program expenses [27] - General and administrative expenses decreased to $1.7 million from $2 million in the same period in 2024, mainly due to lower personnel-related expenses [27] - The net loss for the second quarter of 2025 was $900,000, or $0.11 per share, compared to a net loss of $123.1 million, or $20.52 per share, for the same period in 2024 [28] Business Line Data and Key Metrics Changes - The company is advancing its COVID program with a phase two study of Racutrelvir, aimed at newly diagnosed COVID patients, and expects to report results by year-end 2025 [6][7] - The influenza program is in discussions with BARDA regarding the inclusion of Tivoxavir and Marboxyl in the drug stockpiling initiative, indicating potential commercial opportunities [7][8] Market Data and Key Metrics Changes - Pfizer reported $427 million in sales of Paxlovid for the second quarter of 2025, representing a 70% increase compared to the same period in the prior year, highlighting the competitive landscape in antiviral treatments [7] Company Strategy and Development Direction - The company has reprioritized its clinical trial plans to enhance shareholder value, focusing on antiviral candidates for COVID and influenza [6][29] - The strategy includes maximizing opportunities in the short and medium term, particularly through the development of Racutrelvir and Tivoxavir [29] Management's Comments on Operating Environment and Future Outlook - Management emphasized the ongoing public health threat posed by COVID-19 and the need for effective antiviral treatments, particularly as vaccine immunity wanes [10][14] - The company is committed to addressing the long COVID issue, which affects over 15 million people in the U.S., through its investigational therapies [15] - The management expressed concerns about the potential risks of avian influenza and the need for preparedness measures, advocating for the development of new treatments [21][22] Other Important Information - The company is seeking partnerships to advance its legacy oncology assets, particularly rigosertib, which has shown promising efficacy in a rare disease [24] Q&A Session Summary - The Q&A session was not conducted as the call concluded without any questions being taken from participants [32]